Clinical Trial Update: Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL) [Phase 2]

View source ↗

Summary

Clinical trial PEARL is a Phase II study evaluating erlotinib with concurrent palliative thoracic radiation therapy for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED